Chromatography VideoVideos

Scalable Purification Strategies for Viral Vectors and Vaccines

Large-scale downstream processing of viruses can face a range of obstacles different from those of many biotherapeutics. These challenges mostly arise from the size and complexity of the virus, which can affect product purity and recovery. Improvements of purification tools are necessary to overcome these challenges and must be engineered for easy scalability to meet manufacturing demands. In this video, Dr. Mark Snyder discusses common difficulties when developing purification strategies for vaccine production and gene therapy.
Single-Step Influenza Virus Purification Method Article header image

Single-Step Influenza Virus Purification Using an Anion Exchange Resin

A new and simplified anion exchange chromatographic process for the purification of both live and inactivated cell grown H1N1 influenza viruses was established with a recently developed anion exchanger. The resin is designed with an optimized surface extender and pore size for superior accessibility and large biomolecule binding capacity, aiming to overcome common drawbacks of existing ion exchangers for virus purification.
ArticlesBio-Plex Multiplex AssaysCOVID-19

Evaluating and Understanding the True Spread of COVID-19 through Seroprevalence

Circulation of SARS-CoV-2 in the global population led to the emergence of new variants threatening to undermine vaccine effectiveness. Understanding the immune response and its neutralizing abilities at both the patient level and globally could not only help prevent outbreaks but also mitigate the outcome for future pandemics.
COVID-19General InterestPast WebinarsWebinars

Immunological Response Factors to SARS-CoV-2 in Acquired Immunity

Multiple publications report variation in the duration of acquired immunity to SARS-CoV-2. In this webinar, Bio-Rad scientists review these reports and discuss factors that influence longevity of acquired immunity. Learn about the mechanisms behind acquired immunity and how cytokine and chemokine activity, preexisting conditions, and more can affect immunity duration.

How to Make a Successful Vaccine

As phase 3 clinical trials of investigational vaccines for COVID-19 begin in the U.S., you may be wondering what it takes to make an effective vaccine? In case you missed it, check out our Hanging with My Chromies podcast, episodes 6 and 10 on vaccine development and viral spread, and learn about the role chromatography plays in making a successful vaccine.